LLY Stock Analysis: Buy, Sell, or Hold?
LLY - Eli Lilly & Co.
$1160.00
3.27 (0.28%)
â˛
5d:
-5.97%
30d:
+3.45%
90d:
+9.01%
WAIT
LOW Confidence
Analysis Updated: Sep 1, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When LLY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LLY is fairly priced but lacks strong directional signals. At -2.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LLY is fairly priced but lacks strong directional signals. At -2.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2299.54
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$1427.83
18.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LLY is currently trading at $1160.00, which is considered slightly low relative to its 30-day fair value range of $1157.54 to $1234.99. The stock's valuation (Forward PE: 24.6) is in line with its historical norms (26.2). Remarkably, the market is currently pricing in an annual earnings decline of 2.1% over the next few years. This pessimistic expectation contrasts with the company's recent 26.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, LLY is in a strong uptrend. The price is currently testing key support at $1147.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1315.04 (+13.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LLY is in a strong uptrend. The price is currently testing key support at $1147.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1315.04 (+13.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1157.54 -
$1234.99
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
Protect Your Profits
Holding LLY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($1315.04)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1157.54 -
$1234.99
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1147.00
Resistance Level
$1292.65
Current Trend
Strong Uptrend
Technical data as of
Sep 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.56
Wall Street Target
$1315.04
(+13.4%)
Revenue Growth (YoY)
47.7%
Earnings Growth (YoY)
26.2%
Profit Margin
33.5%
Valuation Discount vs History
-2.1% cheaper
PE vs Historical
24.6 vs 26.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.1%
(market-implied from PE analysis)
1-Year Target
$1135.64
(-2%)
2-Year Target
$1111.79
(-4%)
3-Year Target
$1088.44
(-6%)
3-Yr Target (if PE normalizes)
(PE: 25â26)
$1161.19
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.6, Growth: 28.7%)
$2470.74
(+113%)
Base:
(SPY PE: 20.1, Growth: 28.7%)
$2022.18
(+74%)
Bear:
(PE: 17.1, Growth: 28.7%)
$1718.85
(+48%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (39x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 38.76 | Current EPS (TTM): $29.84
Bull Case
$2014.10
(+74%)
Analyst growth 58.3%, PE expands to 42.6
Base Case
$1831.00
(+58%)
Market implied 58.3%, PE stable at 38.8
Bear Case
$786.58
(-32%)
Severe decline -20.0%, PE contracts to 33.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.6 to 26.2
Stabilization Target:
$1237.53
(+6.7%)
PE Expansion Potential:
+6.7%
Share & Embed Analysis
Last updated: September 02, 2026 4:43 AM ET
Data refreshes hourly during market hours. Next update: 5:43 AM
Data refreshes hourly during market hours. Next update: 5:43 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LLY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
SELL
2026-03-13
Featured in Portfolios
LLY is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 42 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 55 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$236 | 45 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 44 HOLD |
|
BMY
Bristol-Myers Squibb ComâĻ |
HOLD
29 analysts |
$66 | 44 HOLD |
Advanced LLY Option Strategies
Professional options setups generated by AI based on today's LLY price and gamma walls.
